News

Back

OncoDNA Closes Successful Series B Investment Round

February 14th 2020

BioPark

OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing. The new funding will support rapid international growth, accelerate software development and hiring initiatives.  Please discover the press release here.